GLP-1 agonists — session overview
- Why GLP-1 biology matters in diabetes and obesity
- How incretin signalling links gut, pancreas, appetite and metabolism
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity. In this episode, Dr Anzal Qurbain explains how they work, the landmark cardiovascular trials that changed prescribing practice, the significant weight loss data, and the key safety considerations every prescriber needs to know.
This on-demand webinar is a recorded episode from the Drug Class Explainers series.
Listen to the full session below and earn 0.5 CPD hours upon completion.
Guidelines, mechanisms, trials and CPD connected to this webinar topic.
Get Diabetes / Metabolic webinar, podcast and CPD releases in your ClinicaliQ preferences.